These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32586921)

  • 1. Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments.
    Gendebien Z; von Frenckell C; Ribbens C; André B; Thys M; Gangolf M; Seidel L; Malaise MG; Malaise O
    Ann Rheum Dis; 2021 Jun; 80(6):e94. PubMed ID: 32586921
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.
    Carbillon L; Benbara A; Boujenah J
    Ann Rheum Dis; 2021 Apr; 80(4):e54. PubMed ID: 32475831
    [No Abstract]   [Full Text] [Related]  

  • 3. Systemic lupus erythematosus.
    Kiriakidou M; Cotton D; Taichman D; Williams S
    Ann Intern Med; 2013 Oct; 159(7):ITC4-1. PubMed ID: 24081299
    [No Abstract]   [Full Text] [Related]  

  • 4. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
    Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
    He F; Luo Q; Lei M; Fan L; Shao X; Hu K; Qin S; Yu N; Cao J; Yang L
    Clin Rheumatol; 2020 Sep; 39(9):2803-2810. PubMed ID: 32725351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.
    Gupta S; Nakabo S; Chu J; Hasni S; Kaplan MJ
    Ann Rheum Dis; 2023 Oct; 82(10):e215. PubMed ID: 33452005
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon
    Konig MF; Gianfrancesco M; Yazdany J; Robinson PC
    Ann Rheum Dis; 2021 Apr; 80(4):e55. PubMed ID: 32475834
    [No Abstract]   [Full Text] [Related]  

  • 8. Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.
    Martelli Júnior H; Marques NP; Marques NCT; Gomes de Lucena E; Martelli DRB; Oliveira EA
    Ann Rheum Dis; 2023 Nov; 82(11):e225. PubMed ID: 33883160
    [No Abstract]   [Full Text] [Related]  

  • 9. Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics.
    Mendel A; Bernatsky S; Askanase A; Bae SC; Clarke AE; Costedoat-Chalumeau N; Gladman DD; Gordon C; Hanly J; Jacobsen S; Kalunian K; Mak A; Mosca M; Pons-Estel BA; Ruiz-Irastorza G; Urowitz M; Vinet É
    Ann Rheum Dis; 2021 Feb; 80(2):1-2. PubMed ID: 32586918
    [No Abstract]   [Full Text] [Related]  

  • 10. Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'.
    Nikpour M; Teh B; Wicks IP; Pellegrini M
    Ann Rheum Dis; 2021 Mar; 80(3):e33. PubMed ID: 32471898
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to: 'Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine by Mathian
    Mathian A; Amoura Z
    Ann Rheum Dis; 2022 Nov; 81(11):e217. PubMed ID: 33239273
    [No Abstract]   [Full Text] [Related]  

  • 12. Systemic lupus erythematosus: safe and effective management in primary care.
    Michalski JP; Kodner C
    Prim Care; 2010 Dec; 37(4):767-78, vii. PubMed ID: 21050957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to: 'Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'' by Nikpour
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 Mar; 80(3):e34. PubMed ID: 32471900
    [No Abstract]   [Full Text] [Related]  

  • 14. Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Mathian
    Notz Q; Meybohm P; Kranke P; Weismann D; Lotz C; Schmalzing M
    Ann Rheum Dis; 2022 Nov; 81(11):e216. PubMed ID: 32859609
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of systemic lupus erythematosus: myths, certainties and doubts].
    Ruiz-Irastorza G; Danza A; Khamashta M
    Med Clin (Barc); 2013 Dec; 141(12):533-42. PubMed ID: 23622892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus receiving immunosuppressive drugs.
    Feldman CH; Liu J; Feldman S; Solomon DH; Kim SC
    Lupus; 2017 Jun; 26(7):682-689. PubMed ID: 27799438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic lupus erythematosus and risk of infection.
    Barber MRW; Clarke AE
    Expert Rev Clin Immunol; 2020 May; 16(5):527-538. PubMed ID: 32478627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Lupus Erythematosus: Primary Care Approach to Diagnosis and Management.
    Lam NC; Ghetu MV; Bieniek ML
    Am Fam Physician; 2016 Aug; 94(4):284-94. PubMed ID: 27548593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations.
    Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
    Clin Rheumatol; 2019 Oct; 38(10):2785-2791. PubMed ID: 31175481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to: 'Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey' by Plüß
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 Apr; 80(4):e53. PubMed ID: 32616603
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.